Mint: In a transfer that might probably pave the way in which for Pfizer and Johnson & Johnson’s covid-19 vaccines in India, the Centre on Tuesday mentioned it could permit the granting of emergency licensure for vaccines which have acquired authorization within the US, UK, Europe, Japan or from the World Well being Group (WHO).
That is excellent news and a wise transfer. However what’s irritating is that Pfizer was the first company to apply for an EUA from India means again in December of 2020 however India demanded that they conduct a medical research on the Indian inhabitants and Pfizer pulled its utility. In different phrases, India may have had a 3rd vaccine authorized and in use however “vaccine nationalism” reared its ugly head. Solely now, because the our bodies burn within the streets, has the Indian authorities acknowledged that the FDA and the EMA are most likely fairly cautious judges of security and efficacy.
It’s true that the chilly storage necessities make the Pfizer vaccine considerably troublesome to make use of in India’s villages however it could have been superb to make use of within the main cities.
Naturally, the FDA and the EMA also needs to recognize each other as peer regulators.